From: Application of the ACOSOG Z0011 criteria to Chinese patients with breast cancer: a prospective study
Clinicopathological characteristics | Total (n=142) | SLNB alone (n=115) | ALND (n=27) |
---|---|---|---|
Age (median, range) | 52 years (26–82) | 52 years (29–82) | 44 years (26–69) |
Age group, no. (%) | |||
 ≤ 50 | 68 (47.89) | 51 (44.35) | 17 (62.96) |
 > 50 | 74 (52.11) | 64 (55.65) | 10 (37.04) |
Clinical T stage, no. (%) | |||
 cT1 | 112 (78.87) | 90 (78.26) | 22 (81.48) |
 cT2 | 30 (21.13) | 25 (21.74) | 5 (18.52) |
Pathological T stage, no. (%) | |||
 pT1 | 103 (72.54) | 81 (70.43) | 22 (81.48) |
 pT2 | 39 (33.91) | 34 (29.57) | 5 (18.52) |
Tumor histology, no. (%) | |||
 Ductal | 119 (83.80) | 95 (82.61) | 24 (88.89) |
 Lobular | 15 (10.56) | 13 (11.30) | 2 (7.41) |
 Other | 8 (5.63) | 7 (6.09) | 1 (3.7) |
Lymphovascular invasion, no. (%) | |||
 Present | 33 (23.24) | 26 (22.61) | 7 (25.93) |
 Absent | 68 (47.89) | 60 (52.17) | 8 (29.63) |
 Missing | 41 (28.87) | 29 (25.22) | 12 (44.44) |
Hormone status, no. (%) | |||
 Positive | 117 (82.39) | 92 (80.0) | 25 (92.59) |
 Negative | 25 (17.61) | 23 (20.0) | 2 (7.41) |
HER2 status, no. (%) | |||
 Negative | 118 (83.10) | 96 (83.48) | 22 (81.48) |
 Positive | 21 (14.79) | 17 (14.78) | 4 (14.81) |
 Unknown | 3 (2.11) | 2 (1.74) | 1 (3.70) |
Number of positive SLN, no. (%) | |||
 1 | 109 (76.76) | 94 (81.74) | 15 (55.56) |
 2 | 33 (23.24) | 21 (18.26) | 12 (44.44) |
Adjuvant chemotherapy, no. (%) | |||
 Yes | 129 (90.45) | 102 (88.70) | 27 (100.00) |
 No | 13 (9.15) | 13 (11.30) | 0 (0.00) |
Adjuvant endocrine therapy, no. (%) | |||
 Yes | 115 (80.99) | 92 (80.00) | 23 (85.19) |
 No | 27 (19.01) | 23 (20.00) | 4 (14.81) |
Radiotherapy, no. (%) | |||
 Yes | 127 (89.44) | 101 (87.83) | 26 (96.30) |
 No | 15 (10.56) | 14 (12.17) | 1 (3.70) |